Locoreginal radioimmunotherapy with 186Re-labeled monoclonal antibody in treating small peritoneal carcinomatosis of colon cancer in mice in comparison with 131I-counterpart.
The efficacy of locoregional radioimmunotherapy (RIT) in treating peritoneal tumors of colon cancer of <2 mm in diameter was examined at maximum tolerated doses, focusing the comparison between 186Re and 131I labeled to an anti-colorectal cancer IgG1. Estimated radiation doses to tumors were considerably higher with 186Re-RIT than with 131I-RIT. The advantage of 186Re-RIT decreased with decreasing tumor size, but 186Re-RIT delivered 1.6-times higher radiation to tumors of 1 mm. Consequently, 186Re-RIT attained better survival of mice than 131I-RIT or chemotherapy with 5-fluorouracil did. Therefore, locoregional 186Re-RIT may be an option in an adjuvant setting of colon cancer with high risk of peritoneal dissemination.
Kinuya
Seigo
S
Department of Biotracer Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8640, Japan. kinuya@med.kanazawa-u.ac.jp
Yokoyama
Kunihiko
K
Izumo
Mishiroku
M
Sorita
Takami
T
Obata
Takashi
T
Mori
Hirofumi
H
Shiba
Kazuhiro
K
Watanabe
Naoto
N
Shuke
Noriyuki
N
Michigishi
Takatoshi
T
Tonami
Norihisa
N
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003110:Colonic Neoplasms / Q000532:radiotherapy*; D004195:Disease Models, Animal; D007274:Injections, Intraperitoneal; D007457:Iodine Radioisotopes / Q000008:administration & dosage* / Q000493:pharmacokinetics; D020714:Maximum Tolerated Dose; D051379:Mice; D010534:Peritoneal Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D016499:Radioimmunotherapy / Q000379:methods; D011868:Radioisotopes / Q000493:pharmacokinetics; D012211:Rhenium / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014018:Tissue Distribution
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes; D011868:Radioisotopes; D012211:Rhenium